Insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains by Linda Adzovic et al.
JOURNAL OF 
NEUROINFLAMMATION
Adzovic et al. Journal of Neuroinflammation  (2015) 12:63 
DOI 10.1186/s12974-015-0282-zRESEARCH Open AccessInsulin improves memory and reduces chronic
neuroinflammation in the hippocampus of young
but not aged brains
Linda Adzovic1,2, Ashley E Lynn2, Heather M D’Angelo1, Alexis M Crockett2, Roxanne M Kaercher1, Sarah E Royer2,
Sarah C Hopp2 and Gary L Wenk1,2*Abstract
The role of insulin in the brain is still not completely understood. In the periphery, insulin can decrease inflammation
induced by lipopolysaccharide (LPS); however, whether insulin can reduce inflammation within the brain is unknown.
Experiments administrating intranasal insulin to young and aged adults have shown that insulin improves memory. In
our animal model of chronic neuroinflammation, we administered insulin and/or LPS directly into the brain via the
fourth ventricle for 4 weeks in young rats; we then analyzed their spatial memory and neuroinflammatory response.
Additionally, we administered insulin or artificial cerebral spinal fluid (aCSF), in the same manner, to aged rats and then
analyzed their spatial memory and neuroinflammatory response. Response to chronic neuroinflammation in young rats
was analyzed in the presence or absence of insulin supplementation. Here, we show for the first time that insulin
infused (i.c.v.) to young rats significantly attenuated the effects of LPS by decreasing the expression of
neuroinflammatory markers in the hippocampus and by improving performance in the Morris water pool task. In
young rats, insulin infusion alone significantly improved their performance as compared to all other groups.
Unexpectedly, in aged rats, the responsiveness to insulin was completely absent, that is, spatial memory was still
impaired suggesting that an age-dependent insulin resistance may contribute to the cognitive impairment observed in
neurodegenerative diseases. Our data suggest a novel therapeutic effect of insulin on neuroinflammation in the young
but not the aged brain.
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Aging is characterized by chronic low-level neuroinflam-
mation [1-4]. The consequences of neuroinflammation,
associated with microglial activation, operating across a
timescale of decades, are carefully regulated until, due to
normal aging, there is a gradual shift to a non-equilibrium
state that is permissive for neurodegenerative processes
[5-7]. Vulnerable brain regions, particularly the hippocam-
pus, are likely exposed for many decades to a complex
and varying blend of microglia in alternative activation
states [8-10]. Dysregulation of insulin signaling is also as-
sociated with many age-related neurodegenerative diseases* Correspondence: wenk.6@osu.edu
1Department of Psychology, Ohio State University, 1835 Neil Ave, Columbus,
OH 43210, USA
2Department of Neuroscience, Ohio State University, Columbus, OH 43210,
USA
© 2015 Adzovic et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.that also present with chronic neuroinflammation and
that may contribute to cognitive deficits [11-13]; however,
the link between these two characteristics and their inter-
action in the neurodegenerative processes has not been
fully investigated.
In the periphery, insulin can decrease the inflammatory
response [14] by reducing the production of cytokines,
such as interleukin-1β (IL-1β) and tumor necrosis factor
alpha (TNFα), and by decreasing protein kinase C zeta
(PKCζ) protein expression [15,16]. PKCζ protein was
shown to play a role in the activation of nuclear factor
kappa B (NF-κB) pathway [17] which is necessary to
enhance the inflammatory response. Interestingly, insu-
lin was reported to suppress the expression and activity
of inducible nitric oxide synthase (iNOS) [18] and
cyclooxygenase-2 (COX-2) [19] by diminishing the acti-
vation of the NF-κB pathway [20] with a consequentl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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inflammatory cytokine IL-1β can phosphorylate the
insulin receptor substrate protein at Serine 307 [21]
which may then negatively or positively [22,23] regu-
late insulin signaling. It is unknown whether insulin
exhibits a similar neuroprotective role in the brain.
The epidemiological data suggest that brain insulin re-
sistance flanks both cognitive decline and progressive
neuroinflammation in neurodegenerative diseases [11];
in particular, type II diabetes represent a risk factor to
develop Alzheimer’s disease [24-28].
The insulin receptor (IR) is abundant in neurons and
is highly concentrated in the hippocampus, particularly
around the synaptic area [29,30]. Insulin can reach the
brain by passing through the blood brain barrier (BBB)
and can also be synthesized by neurons and released
upon membrane depolarization [31]. Insulin signaling
plays an important role in neuronal survival [32] and in
learning and memory [33]. Intranasal insulin administra-
tion improved memory in young human subjects [34-36]
and in patients with cognitive deficits associated with
mild-stage Alzheimer’s disease [11,37]. The molecular
mechanism through which insulin improves memory is
still under investigation; however, recently, it was shown
that insulin phosphorylates AMPA receptor at Serine
831 that is associated with the early stage and mainten-
ance of long-term potentiation [37].
In the current study, we analyzed the role of insulin in
spatial memory and in the inflammatory process within
the hippocampus for memory regulation. Several labora-
tories have used intranasal insulin administration to de-
liver insulin to the brain [34,35]; we infused insulin
directly into the young rat brain, in the presence or ab-
sence of neuroinflammation, for 4 weeks; we used re-
combinant human insulin which was shown to activate
the insulin signaling in murine models [37,38].
In addition to analyzing the role of insulin in young rats,
we also analyzed the role of insulin in aged rats. We
assessed spatial memory and compared the behavioral and
biochemical consequences of insulin administration. We
have previously chronically infused low-doses of lipopoly-
saccharide (LPS) into the fourth ventricle to selectively
stimulate the Toll-like receptor-4 (TLR4) complex
expressed by microglia [39,40]. Administered in this fash-
ion, the overall dose of LPS is not sufficient to produce
any peripheral manifestations of infectious disease pro-
cesses (such as elevated serum levels of inflammatory cy-
tokines) or downregulation in TLR4 gene expression in
the brain [41-47].
Here, for the first time, we show that insulin decreased
the inflammation in the hippocampus of young rats by
reducing the neuroinflammatory response and by rescuing
spatial memory. Furthermore, insulin improved spatial
memory in young rats. In contrast, we report that the agedbrain was unresponsive to the insulin infusion. These re-
sults offer insight into the potential role of age-dependent
insulin resistance with the cognitive decline associated
with Alzheimer’s disease.
Materials and methods
Subjects and study design
Two separate studies were conducted in parallel. The
first study used 64 young (3 months old) male F-344 rats
(Harlan Sprague-Dawley) rats that were divided into four
groups: artificial cerebral spinal fluid (aCSF)-, aCSF + in-
sulin-, LPS-, and LPS + insulin-infused (i.c.v.). The sec-
ond study used 27 aged (21 months old) male F-344 rats
(Harlan Sprague-Dawley) divided into two groups:
aCSF- and i.c.v. Comparisons were made to each age
group’s respective aCSF control. Aged rats were not in-
fused with LPS for three reasons: first, we have previ-
ously shown [41] that when LPS was chronically infused
into the fourth ventricle of young and aged rats, only the
young rats demonstrated impaired spatial memory per-
formance in the Morris water maze task; the perform-
ance of aged rats was not further impaired by chronic
infusion with LPS. Second, chronic infusion of LPS into
the fourth ventricle of old rats did not significantly in-
crease the number of activated microglia [41]. Third, the
intent of our study was to determine whether insulin in-
fusion in the brain could reduce the naturally occurring
age-associated neuroinflammation.
The rats were maintained on a 12/12-h light-dark
cycle in a temperature-controlled room (22°C) with free
access to food and water and with lights off at 09:00 AM.
All rats were given health checks, handled upon arrival,
and allowed at least 1 week to adapt to their new environ-
ment prior to surgery. All rats were sacrificed during the
dark phase of the diurnal cycle. Body weight and blood
samples, withdrawn from the saphenous vein, were ac-
quired weekly for the glucose and weight change ana-
lysis. We certify that the experiments were carried out
in accordance with the National Institute of Health
Guide for the Care and Use of Laboratory Animals
(NIH Publications No. 80-23) revised 1996. We also
certify that the formal approval to conduct the experi-
ments has been obtained from the Institutional Animal
Care and Use Committees of The Ohio State University.
Surgery
aCSF (140 mM NaCl, 3.0 mM KCl, 2.5 mM CaCl2,
1.0 mM MgCl2, and 1.2 mM Na2HPO4 adjusted to
pH 7.4), LPS (0.25 μg/hr, 1 mg/ml prepared in aCSF; E.
coli, serotype 055:B5, TCA extraction, Sigma-Aldrich,
St. Louis, MO, USA) or insulin (5 mU per day, insulin
human recombinant cat #I2643, Sigma-Aldrich, St.
Louis, MO, USA) were chronically (4 weeks) infused
via a double cannula that was implanted into the fourth
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lambda) and attached (via Tygon tubing, 0.06 O.D.,
Saint Gobain, Valley Forge, PA, USA) to an osmotic
minipump (Alzet model #2004, to deliver 0.25 μl/hr;
Durect Corp., Cupertino, CA, USA) as previously de-
scribed [41,46,48]. A dosage of 5 mU insulin per day
was shown to have no effect on daily food intake or
body weight [49]. All the rats were infused for 28 days
until the tissue collection day. Post-operative care in-
cluded lidocaine 1% solution applied to the exposed
skin upon closure and 2 ml of isotonic saline by sub-
cutaneous injection to prevent dehydration during re-
covery. The rats had 23 days post-surgery recovery
before starting the behavioral task.
Behavioral testing and sacrifice
Morris water maze task (MWM): the rats were handled
daily for 5 days before behavioral testing began. Spatial
learning ability was assessed for all rats using the
MWM, with a 170 cm diameter water pool with gray
walls. The water was maintained at room temperature
(22°C). The pool was in the center of a room with mul-
tiple visual stimuli as distal and proximal cues. The clear,
circular escape platform was 10 cm in diameter. For the
spatial (hidden-platform) version of the water task, a cir-
cular escape platform was present in a constant location,
submerged 2.5 cm below the water surface. The rats
were tracked using Noldus Ethovision 3.1 tracking and
analysis system (Noldus, Leesburg, VA,USA). Beginning
24 days after surgery, each rat performed 6 trials per day
for four consecutive days (24 trials total), with a 60-min
inter-trial interval. Each rat was released into the water
on each trial from one of six locations spaced evenly
around the pool, which changed so that the rats did not
start from the same location twice in 1 day. After the rat
found the escape platform or swam for a maximum of
60 s, it was allowed to remain on the platform for 30 s.
At the end of the fourth day, the platform was removed
and a standard probe trial was conducted. After the
probe test, all rats were also tested with the platform
raised 2 cm above the surface of the water in a location
different from the previous trials in order to control def-
icits in visual acuity. The effects of normal aging, insulin,
and/or inflammation in cognition were assessed by com-
paring their latency to find the platform.
The day after the completion of behavioral testing,
each rat was deeply anesthetized with isoflurane. Rats
used for histology were prepared for a transcardiac perfu-
sion with cold saline containing 1 U/ml heparin, followed
by 4% paraformaldehyde in 0.1 M phosphate buffer,
pH 7.4. The brains were then post-fixed overnight in the
same fixative and then stored (4°C) in phosphate buffer sa-
line (PBS), pH 7.4. Rats used for biochemistry from each
group were rapidly decapitated; their hippocampi werequickly dissected on ice. The left and right hippocampi
were randomly chosen for either protein or gene expres-
sion analyses and stored (−80°C) until processed. Blood
was collected during the rapid decapitation procedure.
After centrifugation at 4°C for 15 min 2,500 × g, serum
was collected and assayed.
Immunocytochemistry
The immunocytochemistry was performed as previously
described [50]. The monoclonal antibody OX-6 (final di-
lution 1:200, Pharmigen, San Diego, CA, USA) was used
to visualize activated microglial cells only. This antibody
is directed against class II major histocompatibility com-
plex (MHC II) antigen, an indicator of activation. The
location of immunohistochemically defined cells was ex-
amined by light microscopy. Quantification of cell dens-
ity in the reconstructed hippocampal coronal sections
(at least five sections from each rat) was assessed with
Nikon 80i documentation system with DS-5 M-L1
digital camera using Elements 3.1 (Nikon Instruments,
Melville, NY, USA) and quantified using MetaMorph im-




Frozen (−80°C) hippocampi were placed in a BioPlex
Cell Lysis solution (Bio-Rad, Richmond, CA, USA), and
total proteins were extracted according to the manufac-
turer’s instructions. Hippocampal levels of TNFα,
interleukin-1-alpha (IL-1α), IL-1β, and IL-6 were
quantified simultaneously with a magnetic bead im-
munoassay (Bio-Rad, BioPlex Pro Rat Standard, 171-
K1002M, Bio-Rad, Richmond, CA, USA). A mixture of
distinct capture beads (fluorescently dyed micro-
spheres) each with a specific spectral address and con-
jugated to an antibody against one of the cytokines
listed above were quickly dispensed across a 96-well
plate and protected from light. Samples and antigen
standards were added in duplicate and incubated for
1 h at 700 RPM at RT; unbound materials were washed
away (3×). Then biotinylated detection antibodies di-
rected against each of the proteins were added for
30 min at 700 RPM at RT; unbound materials were
washed away (3×). Each well was then incubated for
10 min at 700 RPM at RT with a reporter dye, streptavidin-
phycoerythrin conjugate (SA-PE), which binds to the detec-
tion antibody; unbound materials were washed away (3×).
Each well was then suspended in assay buffer and shaken at
1,100 RPM for 30 s. Plates were analyzed using a Bio-Plex
MAGPIX multiplex reader (Bio-Rad, Richmond, CA,
USA). Values were compared to standard curves. All of the
biomarkers were well above the background detection level
of the assay. Protein was quantified in brain homogenates
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USA). The results are reported as picograms/ml protein.
Western blot analyses
The hippocampi were lysed and analyzed using Western
blot as previously described [37]. The antibodies for pro-
tein kinase-B (AKT), p-Akt (Ser 473), p-Akt (Thr 308),
insulin receptor substrate-1 (IRS-1), IGF1-R, and the
secondary anti-rabbit IgG, HRP-linked were supplied by
Cell Signaling Technology (Danvers, MA, USA); the
PKCζ (C-20) antibody was supplied by Santa Cruz Bio-
technology (Dallas, TX, USA); and the insulin receptor
antibody was supplied from Abcam (Cambridge, UK).
The images were acquired with the enhanced chemilu-
minescence detection system (Pierce, Waltham, MA,
USA). The data were quantified with Image-J software
from NIH.
Reverse transcription polymerase chain reaction
Total RNAs was extracted from hippocampi using Pure-
Zol (Bio-Rad, Richmond, CA, USA) followed by clean-up
with a NucleoSpin RNA II kit (Macherey-Nagel, Düren,
Germany) according to the manufacturers’ instructions.Table 1 Primer sequences for gene expression analyses
Gene Accession number Primer sequences F: forwa
IL1ß NM_031512 F: ACCTGCTAGTGTGTGATGT
R: AGGTGGAGAGCTTTCAGC
TNFα X66539.1 F: CTGGCCAATGGCATGGATC
R: AGCCTTGTCCCTTGAAGAG
GADPH NM_017008 F: TGACTCTACCCACGGCAAG
R: ACGACATACTCAGCACCA
CREB1 NM_134443 F: TGTTCAAGCTGCCTCTGGT
R: ACCTCTCTCTTTCGTGCTGC
BDNF BC087634 F: AGCCTGTGTACTTTGTGTCC
R: TGGACGTTTGCTTCTTTCAT




NGF β NM_001277055 F: ACTTCCAGGCCCATGGTAC
R: ATGTCCGTGGCTGTGGTCT




SYN1 NM_019133 F: TCTCCAGCACACCTTGCTC
R:CTGGTTGGTGGATAGTAGG
BDNF, brain-derived neurotrophic factor; CaMKIIα, Ca2+/calmodulin-dependent pro
glyceraldehyde-3-phosphate dehydrogenase; IL, interleukin; iNOS, inducible nitric
protein kinase C-zeta; PSD95, postsynaptic density protein 95; SYN1, Synapsin I; TThe total RNA (1 μg) from each sample was reverse-
transcribed using the iScript reverse transcription Supermix
for RT-qPCR (Bio-Rad, Richmond, CA, USA) to generate a
cDNA library. Primers (see Table 1) were designed for each
gene using the PrimerQuest software (Integrated DNA
Technologies, Coralville, IA, USA; Table 1). Primers and
Sso Advanced SYBR Green Supermix (BioRad, Richmond,
CA, USA) were prepared with RNase-free water. For PCR
amplification, mix (19 μl) was added to RT reaction (1 μl)
previously diluted (1:20). Assays were run in triplicate on
the CFX96, C1000 Thermal Cycler (Bio-Rad, Richmond,
CA, USA). Amplification conditions were as follows: 95°C
for 30 s, 40 cycles of PCR (denaturation: 95°C for 5 s, an-
nealing/extension: 60°C for 30 s), and melting curves. Two
negative controls were performed during each quantitative
PCR experiment: reaction without the reverse transcription
to confirm the absence of genomic DNA contamination
and samples with no added cDNA template to prove the
absence of primer dimers. Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) was used as a housekeeping gene.
The cycle (Ct) at which expression levels crossed threshold
was normalized to the Ct of the housekeeper GAPDH, pro-























tein kinase II-alpha; CREB1, cAMP response element-binding protein-1; GAPDH,
oxide synthase; IR, insulin receptor; NGF β, nerve growth factor-beta; PRKCζ,
NF-α, tumor necrosis factor-alpha.
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controls.Statistic analyses
Statistical analyses were conducted out using SPSS
software (version 20). A general linear model, re-
peated measures analysis of variance (rANOVA) and
Fisher’s protected least significant difference for post
hoc multiple comparisons were used. The Fisher’s
post hoc test was utilized only if the overall F-value
was significant for the effect. P < 0.05 was considered
statistically significant. Graphs were prepared using
GraphPad Prism (GraphPad Software, La Jolla, CA,
USA) and are shown with the standard error of the
mean represented by error bars. At least five rats for
each treatment were used to obtain the data for
gene expression, cytokine essay, and Western blot
detection.Figure 1 Morris water maze performance. (A) Latency: in the young gro
performance recovered when insulin was infused with LPS (see text). Surprisin
all other groups. Conversely, in the aged rats, insulin did not improve perform
significantly improved performance versus LPS and LPS/insulin groups (P < 0.0
in the insulin group (P < 0.05) over the 4 days while it was greater in the LPS
(P < 0.01). Insulin treatment reduced the distance swam as compared to aCSF
as compared to aCSF and insulin (P < 0.05). (Stars) The aged rats showed no dResults
Behavior
An rANOVA performed on the latency results (Figure 1A)
revealed an overall main effect of treatment group (F5,83 =
13.2, P < 0.0001) and testing day (F3,249 = 52.5, P < 0.0001).
Post hoc analyses determined that performance was sig-
nificantly impaired by LPS infusion (P = 0.013) and the
age of the rat (P < 0.001), as compared to young aCSF-
infused rats. Insulin treatment significantly improved the
performance in young rats, as compared to either aCSF-
infused (P = 0.008) or LPS-infused (P = 0.028) young rats.
Insulin treatment did not improve the performance of the
aged rats (P > 0.05) as compared to aCSF-infused aged
rats.
An rANOVA of swim speed (Figure 1B) revealed an
overall main effect of treatment group (F5,83 = 18.8, P <
0.001). Post hoc analyses determined that swim speed was
significantly impaired by the age of the rat (P < 0.001).
Neither the LPS nor insulin infusions had significantups, the performance was significantly impaired by LPS infusion;
gly, the young rats receiving only insulin performed better compared to
ance as compared to the controls. (B) Velocity: in the young rats, insulin
5). (C) Distance: the distance to find the platform was significantly smaller
group. Insulin/LPS was significant versus LPS (P < 0.05) and versus insulin
(P < 0.05). (D) Probe trial: the performance was impaired by LPS infusion
ifferences, P > 0.05, between aCSF and insulin-infused groups.
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of the distance swam to find the platform (Figure 1C) re-
vealed an overall main effect of treatment group (F5, 529 =
16.1, P < 0.001). Post hoc analyses determined that per-
formance was significantly impaired by LPS infusion (P <
0.001) but not by the age of the rat (P = 0.33). The insulin
infusion significantly reduced the distance swam by the
young rats, as compared to young rats that were infused
with aCSF (P < 0.001). Insulin treatment did not sig-
nificantly reduce the distance swam by the aged rats
(P > 0.05).Figure 2 RT-PCR and cytokine analyses. (A) Gene expression: PRKCZ gen
IRS-1, top right graph, was decreased in the two young groups receiving insu
mRNA was increased in the LPS-infused group, *P < 0.01, versus aCSF and dec
infusion, *P < 0.01, versus aCSF and decreased, ΔP < 0.01, versus LPS + insulin. (
was increased, *P < 0.01, as compared to aCSF. The aged rats showed no diffeReverse transcription PCR and Bioplex
The gene expression, analyzed with general liner model
univariate ANOVA between subjects (Figure 2), revealed
an overall main effect of treatment group on IL-1β
(F3,27 = 3.25, P < 0.001) and TNFα (F3,20 = 5.05, P = 0.007)
gene expression and IL-1β protein levels (F5,25 = 4.51, P
< 0.01). LPS infusion significantly increased IL-1β and
TNFα gene expression (P < 0.01) and IL-1β (P < 0.01)
protein levels. Insulin infusion significantly attenuated
the effect of LPS on IL-1β and TNFα gene expression
and on IL-1β protein level (P < 0.05) but did not decreasee expression did not differ between groups, contrary to the protein level.
lin as compared to the vehicle group Δ (P < 0.05); in the young rats, IL-1β
reased, ΔP < 0.03 versus LPS + insulin. TNFα mRNA was increased by LPS
B) No significant difference, P > 0.05, in the level of TNFα while IL-1β level
rences, P > 0.05, between aCSF and insulin-infused groups.
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cantly decreased in young insulin and insulin + LPS treated
group when compared to the vehicle (P < 0.05).
Aged rats showed no significant changes (P > 0.05) in
IL-1β gene expression or protein levels. Gene expression
of insulin receptor, insulin-like growth factor 1 receptor
(IGF-1 R), cAMP response element-binding protein (CREB),
brain-derived neurotrophic factor (BDNF), PRKCZ, NGFβ,
Ca2+/calmodulin-dependent protein kinase II (CaMKII),
postsynaptic density protein 95 (PSD95), and synapsin I
(SYN1) were also unchanged.
Western blot
An rANOVA revealed an overall main effect of treat-
ment group on hippocampal levels of PKCζ protein
(F5,14 = 6.24, P = 0.003, Figure 3). LPS infusion increased
PKCζ protein levels (P = 0.02) while insulin infusion sig-
nificantly attenuated this effect (P < 0.001). Aged ratsFigure 3 Western blot analyses. The infusion of LPS into the fourth vent
versus aCSF. Insulin treatment reduced, black diamond, P < 0.001, PKCζ leve
for p-AKT Threonine 308 or Serine 473.showed no significant changes (P > 0.05) in PKCζ protein
expression. No significant (P > 0.05) changes in p-AKT
Thr 308, p-Serine 473 AKT, or protein kinase M-zeta
(PKMζ) protein levels were observed. In contrast with
the results in young rats, insulin infusion into the brains
of aged rats did not change PKCζ protein levels (P >
0.05) or induced any change in AKT protein expression
or phosphorylation. Protein levels of CREB, BDNF,
CAMKII, IR, IRS-1, and IGF-1 R were unchanged across
all groups.
Immunohistochemistry
The increased density of MHC II-IR microglia (Figure 4)
in the DG (F1,81 = 11.1, P < 0.001) and CA3 (F1,81 = 5.6,
P = 0.021) regions, but not the CA1 region, of the hippo-
campus was significantly influenced by the LPS infusion.
Insulin treatment significantly (P = 0.005) reduced the
density of MHC II-IR microglia in the DG, but not thericle increased the protein level (A, B) of PKCζ, black square, P < 0.05
ls as compared to LPS. (C, D) No significant changes were observed
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on the density of MHC II-IR microglia.
Discussion
Although the precise role of insulin in the brain is not
fully understood, impaired insulin signaling is a hallmark
of brain aging and many neurodegenerative diseases. In
peripheral tissues and cell cultures, insulin can modulate
the inflammatory process by decreasing LPS-induced ac-
tivation of iNOS [18] and COX-2 activity [19,51]. The
role of insulin in the control of neuroinflammation re-
mains unknown; however, recently it was observed that
insulin decreased the inflammation in an in vivo model
[52]. In the current study, we investigated effects of in-
sulin into the brain using two unique experimental
models of chronic brain inflammation: one experimen-
tally induced by infusion of LPS; the other, naturally oc-
curring associated with normal aging.
We have previously shown that 4 weeks of LPS infusion
into the fourth ventricle of young rats induces the greatest
inflammatory response that is concentrated within theFigure 4 Immunocytochemistry. Photomicrographs and density quantific
the density of MHC II-IR was significantly increased by LPS, P < 0.001, and s
(C), LPS increased the density of MHC II-IR microglial cells; however, co-infu
There were no observed differences in the CA1 region (D) between group
cells. (B) Scale bar: 400 μm for top row figures; 70 μm for bottom row. *P <hippocampus [7,46,47], a decrease in spatial, but not object
recognition, memory [41], an impaired long-term potenti-
ation [43], and an elevated levels of mRNA for multiple
pro-inflammatory cytokines [41,51]. These previous find-
ings suggest that LPS initiates a cascade of biochemical
processes that show time-dependent [50,53] regional and
cell-specific changes that are maximal after 4 weeks of LPS
infusion. Inflammation is represented by an elevation of
wide range of cytokine gene and protein expression. PKCζ
protein levels, which regulates the cytokine expression [16]
and NF-κB signaling [17,54], increased in response to the
LPS infusion and decreased in response to the infusion of
insulin leaving the phosphorylation of AKT at Threonine
308 and Serine 473 unchanged. In contrast, the PRKCζ
gene, which encodes for both protein isoforms, PKCζ and
PKMζ, was not affected by the LPS infusion or insulin infu-
sion, suggesting a selective post-translational control of the
production of these two proteins that are known to have
unique molecular roles. The LPS infusion also increased
the gene and protein expression of IL-1β as well as the
mRNA level of TNFα; insulin treatment significantlyation of MHC II-IR microglial in hippocampus. In the dentate gyrus (A),
ignificantly decreased in LPS + insulin rats, P < 0.05. In the CA3 region
sion of insulin did not decrease the density of MHC II-IR microglia.
s. There were no age-dependent changes in the density of MHC II-IR
0.05 versus aCSF; +P < 0.05 versus LPS.
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markers. In the periphery, insulin can reverse the effects of
LPS exposure upon the levels of these markers [14]; here,
we show that insulin exhibits similar actions within the
hippocampus.
As previously reported [40,43,47], young rats infused with
LPS demonstrated impaired performance in the MWM
task, as indicated by increased latency and distance swam
to find the platform, as well as increased levels of bio-
markers of brain inflammation. Remarkably, all of these
LPS-induced changes were significantly reversed by insulin
co-infusion. This result confirms that insulin is protective
against neuroinflammation in the young brain; not only did
insulin reduce the impaired latency to find the platform of
LPS infused young rats but also improved swim speed and
the distance swam by the LPS/insulin rats compared to rats
receiving only LPS. The performance of young rats in the
MWM task, across all three measures, was significantly im-
proved by insulin co-infusion. The young rats that received
an infusion of insulin for 4 weeks performed significantly
better than the untreated young rats; they found the hidden
platform more efficiently by swimming a shorter distance
at a slower swim speed.
We speculated that the specific molecular mechanism(s)
underlying insulin’s ability to decrease the level of pro-
inflammatory markers in the hippocampus of LPS-infused
young rats and improve performance in normal young
rats might be due to changes in several memory-related
biomarkers such as CREB, CaMKII, PSD95, BDNF, NGF,
and SYN1. However, none of these markers presented dif-
ferences in their gene or protein expression. In contrast,
insulin treatment did not improve performance of aged
rats in the MWM task, did not alter the endogenous ex-
pression of IL-1β, TNFα, PKCζ genes, or protein levels,
and did not alter the number of activated microglia within
their hippocampus.
Aging is a risk factor for insulin resistance [55], and in-
sulin signaling decrease is believed to be the cause that
triggers the neurodegenerative processes [56], particularly
in AD. In the current study, although IR and IGF-1R gene
and protein expression was unaltered in the aged and
young rats, we did see a reduced age-dependent insulin
response. We also monitored blood glucose levels as well
as body weight and did not find any significant changes
over the 4 weeks among the different groups or ages. This
result is consistent with the results of other researchers
demonstrating that brain insulin does not control body
weight or peripheral glucose levels [35].
Conclusions
In summary, insulin exerts a protective function against the
consequences of chronic neuroinflammation that is similar
to that observed in in vitro peripheral tissue. Insulin admin-
istered directly into the brain can improve learning andmemory in young animals but not the aged animals. There-
fore, the principle role of insulin in the young brain may be
to influence learning and memory and regulate the beha-
vior of microglia; its actions may be impaired within the
aged brain. Overall, these results reinforce the link between
age-related insulin resistance, neuroinflammation, and
cognitive impairment.
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